Ph2/3 study to evaluate the safety of telisotuzumab in combo with NSCL

Phase II/III Clinical Trial

A Phase 2/3 Randomized Study to Evaluate the Safety Efficacy and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 07005102
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations